To be added: https://www.facebook.com/jessierhawkins/posts/10223429958916146
- “Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19”
- Conclusion:
- Of 2,541 patients, with a median total hospitalization time of 6 days , median age was 64 years, 51% male, 56% African American, with median time to follow-up of 28.5 days. Overall in-hospital mortality was 18.1%
- By treatment:
- hydroxychloroquine + azithromycin, 157/783 (20.1%)
- hydroxychloroquine alone, 162/1202 (13.5%)
- azithromycin alone, 33/147 (22.4%)
- neither drug, 108/409 (26.4%)
- https://doi.org/10.1016/j.ijid.2020.06.099
- Direct PDF Download: Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19
- Conclusion:
- “Chloroquine is a potent inhibitor of SARS coronavirus infection and spread”
- “Conclusion
Chloroquine is effective in preventing the spread of SARS CoV in cell culture. Favorable inhibition of virus spread was observed when the cells were either treated with chloroquine prior to or after SARS CoV infection. In addition, the indirect immunofluorescence assay described herein represents a simple and rapid method for screening SARS-CoV antiviral compounds.” - https://doi.org/10.1186/1743-422X-2-69
- Direct PDF Download: Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
- “Conclusion
- “The cardiotoxicity of antimalarials”
- Malaria Policy Advisory Committee Meeting
- WHO Evidence Review Group Meeting, 13–14 October 2016
Varembé Conference Centre, Geneva, Switzerland - https://www.who.int/malaria/mpac/mpac-mar2017-erg-cardiotoxicity-report-session2.pdf
- Direct PDF Download: The cardiotoxicity of antimalarials
- CDC Flyer on Hydroxychloroquine
MCToon 